AIM ImmunoTech (AIM) announced that the Company’s Board of Directors has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi
- AIM ImmunoTech to not proceed with offering pursuant to registration statement
- AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist
- AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2
- AIM ImmunoTech files to sell units, no amount given